London, UK and Durham, NC – August 6 2021 – As part of PHASTAR's continued growth and success, we are announcing a change in our management structure. From 1st August, Kevin Kane will take on the role of President of PHASTAR. Kevin will continue to work in the business helping to develop new strategic opportunities and ensuring the culture PHASTAR is famous for is maintained across all of PHASTAR’s operating regions. As President, Kevin will continue to work with the board to ensure we maintain focus on quality and excellence in the work we deliver.
At the same time, Andrew MacGarvey has been appointed to the CEO role. Andrew has managed large parts of the business since joining in 2018 and will now take on the responsibility of delivering the company strategy and managing the business as a whole.
London, UK and Durham, NC – 3 August 2021 –PHASTAR, a global specialist biometrics contract research organization offering industry leading data management, data science, statistical consulting and clinical trial reporting services, announced today the appointment of Chuck Gelb as Chief Commercial Officer.
Holding an MBA in Pharmaceutical Management and an MA in Biotechnology, Chuck brings to PHASTAR over 20 years’ experience across pharmaceutical companies and CROs. His unique blend of experience provides critical insight into the needs of pharmaceutical, biotechnology and medical device sponsors, as well as the knowledge to build and manage a large, global sales and marketing team through periods of exponential growth. Furthermore, Chuck is skilled in building brand awareness, vision and market leadership as well as developing global sales strategies.
London, UK and Durham, NC – January 5 2021 –PHASTAR, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support PHASTAR’s growth in biometrics and geographic expansion. Charterhouse is making its investment in partnership with PHASTAR’s Founder and CEO Kevin Kane, who remains a significant shareholder in the business. Kevin and the existing management team will continue to run, manage and operate the business on a day-to-day basis.
"PHASTAR's partnership with Charterhouse is a significant next step in our planned growth strategy," said Kane. "With a new office opening in China our global footprint will widen to include the UK, Europe, Africa, the U.S. and Asia, giving us an opportunity to better serve our clients anywhere in the world. We are extremely grateful for the support our clients and team members have shown over the past 13 years. We anticipate that support will continue to cement PHASTAR’s position as the partner of choice for pharmaceutical companies in their critical statistical and data science projects in the years ahead," he added.
Tokyo, Japan and London, UK – 22nd June 2020 –Phastar, a global CRO offering industry leading statistical consulting, clinical trial reporting, data management and data science services, announced today that the company has officially opened its Tokyo office. Phastar Tokyo will serve as a strategic operational hub to support our Japanese partners and is a key element of the company’s current growth cycle.
“We are delighted to add to our global footprint with our Tokyo office, alongside our existing presence in the US, Europe, Kenya, and Australia,” said Kevin Kane, CEO and founder of Phastar. “This allows Phastar to expand its global, quality, expert biometrics and data science services to Japan.”
San Diego, CA and London, UK – February 11, 2020 –PHASTAR, a global CRO, announced today that the company has chosen San Diego as the site for its new U.S. west coast office, which will be led by Dr. LaRee Tracy, PhD, as Director of Biostatistics. The San Diego office will serve as a strategic operational hub to support PHASTAR’s west coast customers and is a key component of the company’s current 5-year growth plan.
Dr. Tracy brings to PHASTAR more than 24 years’ experience in clinical research, industry regulation and clinical operations, including over 16 years working as an FDA CDER statistician. Her areas of expertise include biostatistics, experimental and observational study design, as well as significant experience with FDA processes and regulations.
“We are excited to add San Diego as our third US office, alongside our existing presence in Europe, Kenya, and Australia,” said Kevin Kane, CEO and founder of PHASTAR. “Dr. Tracy’s vast experience and expertise in both clinical research and FDA processes and regulations marries perfectly with PHASTAR’s reputation as a global, quality, expert provider of biometrics and data science services. We are excited to have someone with her unique background in biostatistics and epidemiology.”
Leading the new office, Dr. Tracy will have input into all business strategies – business development, plans and processes for delivery of clinical trial projects, staff development, recruitment and other areas related to business growth, increasing awareness of PHASTAR’s services in the competitive west coast market. Dr. Tracy will also manage PHASTAR San Diego’s senior technical staff and will be involved in oversight of projects to ensure clinical trial projects are delivered to agreed timelines with optimal quality.
Passionate about public health and science, Dr. Tracy’s 24-year career also includes senior roles in the CDC, FDA, the U.S. Army and the US Public Health Service. She received her PhD in Epidemiology in 2009 from University of Maryland, Baltimore and master’s degree in mathematical statistics from University of Maryland, College Park and is the recipient of several service awards including the Army Meritorious Service Medal, Army Commendation Medal, Army Achievement Medal and the USPHS Commendation Medal. In addition to her academic credentials and service awards, Dr. Tracy’s work has been published in many respected journals.
ABOUT PHASTAR
PHASTAR is a global CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP style arrangements and preferred partnerships. PHASTAR currently has over 250 staff across 10 offices (United States, United Kingdom, Australia, Germany and Kenya) with plans to open additional locations in Asia and the West Coast of the United States to serve prospective and existing clients. PHASTAR’s number one priority is to ensure that the work we produce is of the highest quality. Every project PHASTAR undertakes utilizes our unique internal processes which are designed to ensure optimal quality. All PHASTAR’s statistical, programming, data management and data science staff are trained in the “PHASTAR Discipline” - our in-house approach to data analysis and collection. This comprises a set of common sense (but commonly ignored) principles that, if followed, guarantee error free outcomes. The “PHASTAR Discipline” also includes a series of intranet-based checklists highlighting potential pitfalls and points-to-consider when conducting clinical trials, enabling over 2,500 years of combined technical knowledge to be shared across the company. For further information on PHASTAR contact This email address is being protected from spambots. You need JavaScript enabled to view it..
U.S. Media Contact:
Dawn Fontaine
Ripple Effect Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+(1) 646 851 2624
tellmemore@phastar.com
